Merck & Co restores faith in first-line future for Keytruda lung cancer combo
Shares in New Jersey, USA-based Merck & Co (NYSE: MRK) gained 6% yesterday after the company announced its Phase III KEYNOTE-189 trial of Keytruda (pembrolizumab) met its co-primary endpoints, boosting confidence in its ability to lead in the market for first-line lung cancer therapies.
The trial is designed to compare a combination of the checkpoint inhibitor with Alimta (pemetrexed) and cisplatin or carboplatin, with Alimta and chemo alone, for the first-line treatment of patients with non-small cell lung cancer (NSCLC).
Roger Perlmutter, president of Merck’s research division said the study “showed significant improvement in overall survival and progression-free survival for patients receiving Keytruda.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze